Overview

Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the short term efficacy of a combination immunochemotherapy in patients with relapsed B-cell chronic lymphatic leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
German CLL Study Group
Collaborators:
MedacSchering Onkologie
University of Cologne
Treatments:
Alemtuzumab
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Vidarabine